TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03378466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.

Intervention type: OTHER
Group type: OTHER
Intervention: Venous thromboprophylaxis (VTE)
Description: May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
Study: NCT01132976

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personal Concerns Inventory
Description: This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: No specific motivational interview
Study: NCT02151032

Intervention type: BEHAVIORAL
Intervention: Booklet
Description: Participants read a booklet about colorectal cancer screening tests.

Intervention type: BEHAVIORAL
Intervention: Audio CD
Description: Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.

Intervention type: BEHAVIORAL
Intervention: Video with Non-Moving Images
Description: Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.

Intervention type: BEHAVIORAL
Intervention: Video with Animated Images
Description: Participants watch a video with animated images about colorectal cancer screening tests on an iPad.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaire completion before and after viewing the program.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaire completion before and after viewing the program.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaire completion before and after viewing the program.
Study: NCT04284488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1387 for Injection
Description: APG-1387 IV on Days 1 and 8 of each 21-Day Cycle. The following doses of APG-1387 to be studied: 20, 30, and 45mg. In the phase II, the assigned recommended phase two dose will be administered in all cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg toripalimab IV on Day 1 of each 21-Day Cycle
Study: NCT01924858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2647544 oral
Description: GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of \[18F\]-GSK2647544 and a PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]GSK2647544 IV bolus
Description: \[18F\]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
Study: NCT04168463

Intervention type: DEVICE
Group type: OTHER
Intervention: Two Joy for All robots (one cat and one dog)
Description: Intervention will include the opportunity to interact with the Joy for All robot animals.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two Joy for All robots (one cat and one dog)
Description: Intervention will include the opportunity to interact with the Joy for All robot animals.
Study: NCT01282047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
Study: NCT03196947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APO010
Description: APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
Study: NCT03003338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r and DSV
Description: OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r and DSV
Description: OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match OBV/PTV/r and DSV
Description: Placebo to match OBV/PTV/r and DSV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match OBV/PTV/r and DSV
Description: Placebo to match OBV/PTV/r and DSV
Study: NCT01323764

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ShuntCheck test
Description: Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
Study: NCT02596334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dolutegravir 50mg +abacavir 600mg +lamivudine 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir
Study: NCT02327195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl
Description: Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg of placebo (PO) will be given 2 hours prior to surgery
Study: NCT01880034

Intervention type: OTHER
Intervention: Lipid Emulsion Survey
Study: NCT00665730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sepraspray
Study: NCT04558554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacy-based PrEP delivery
Description: The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacy-based PrEP delivery
Description: The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacy-based PrEP delivery
Description: The intervention is a new model of PrEP delivery that has never been tried before in an African setting: pharmacy-based PrEP delivery.
Study: NCT00493272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrinogen
Description: Fibrinogen behandling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fibrinogen
Description: Fibrinogen behandling
Study: NCT03487055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK006
Description: Subcutaneous injection in the upper arm
Study: NCT03106870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Mixtard
Description: Insulin dose:~* 0.7 IU/Kg (at the second trimester of pregnancy).~* 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Mixtard
Description: Insulin dose:~* 0.7 IU/Kg (at the second trimester of pregnancy).~* 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day.
Study: NCT00725439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talarozole
Description: Oral Dose 1.0 mg once daily
Study: NCT00639990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP
Description: Application of positive end expiratory pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Application of positive end-expiratory pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Application of positive end-expiratory pressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: Application of positive end-expiratory pressure
Study: NCT01774474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study: NCT02583204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onicolife nail drops
Description: The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nail polish
Description: One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
Study: NCT00971893

Intervention type: DRUG
Intervention: Oral Methylprednisolone Tablets
Description: Oral Methylprednisolone tablets given as per locally approved prescribing information
Study: NCT01939197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet
Study: NCT01432795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gliding aids for medical compression stockings
Description: Each subject tests devices:~* 3 gliding aids for stockings with closed tips~* 3 gliding aids for stockings with open tips~* 2 stocking butlers using~* 3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~* 3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~* 2 superimposed compression stockings class 1 (18 - 21 mmHg)
Study: NCT00048568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Intravenous (IV) Solution, - Weight Titered (500 mg \< 60 kg); (750 mg 60-100 kg), )1 gram \> 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, \>= 15 mg, weekly, 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablets, Oral, \>= 15 mg, weekly, 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Tablets, Oral, \>= 15 mg, weekly, 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
Study: NCT02252562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sage Personal Hand Hygiene System
Description: Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
Study: NCT03541564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04033952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
Study: NCT02304588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: 10-20 x 10\^6 cells/20mL
Study: NCT04955262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin (NKTR-214)
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin (NKTR-214)
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ⁸⁹Zr-Df-IAB22M2C
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ⁸⁹Zr-Df-IAB22M2C
Description: Specified dose on specified days
Study: NCT01513083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: Multiple intravenous doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: Multiple intravenous doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine
Description: Multiple intravenous doses
Study: NCT01806922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study: NCT01247259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pangramin®
Description: During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pangramin®
Description: During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
Study: NCT02475915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10